Market Readiness – Tip of the Iceberg
Wall Street Journal – Harris Poll – June 7, 2002
- 1000 people surveyed - - 81% approved using DNA for detection and treatment of disease - - 34% would pay themselves
Bayer acquires Visible Genetics – July 2002
- $61.4 million purchase price is 3 times annual revenues
Roche Diagnostics Revenues up 7% - September 2002
- Growth lead by Molecular Diagnostics where revenue increased 16%
Ken Freeman – UBS Warburg Conference – October 2001
- Quest Diagnostic’s gene-based and esoteric testing units are growing annually at 25% and 10% respectively